头颈部癌症疫苗治疗的进展与挑战
Progress and challenges in the vaccine-based treatment of head and neck cancers.
作者信息
Venuti Aldo
机构信息
Laboratory of Virology, Regina Elena Cancer Institute, Via Messi d'Oro, 156-00158 Rome, Italy.
出版信息
J Exp Clin Cancer Res. 2009 May 27;28(1):69. doi: 10.1186/1756-9966-28-69.
Abstract
Head and neck (HN) cancer represents one of the most challenging diseases because the mortality remains high despite advances in early diagnosis and treatment. Although vaccine-based approaches for the treatment of advanced squamous cell carcinoma of the head and neck have achieved limited clinical success, advances in cancer immunology provide a strong foundation and powerful new tools to guide current attempts to develop effective cancer vaccines. This article reviews what has to be rather what has been done in the field for the development of future vaccines in HN tumours.
摘要
头颈癌是最具挑战性的疾病之一，因为尽管早期诊断和治疗取得了进展，但其死亡率仍然很高。虽然基于疫苗的方法对头颈部晚期鳞状细胞癌的治疗仅取得了有限的临床成功，但癌症免疫学的进展为指导当前开发有效癌症疫苗的尝试提供了坚实的基础和强大的新工具。本文回顾了在头颈肿瘤未来疫苗开发领域必须做而非已经做的事情。
相似文献
1
Progress and challenges in the vaccine-based treatment of head and neck cancers.
J Exp Clin Cancer Res. 2009 May 27;28(1):69. doi: 10.1186/1756-9966-28-69.
2
Vaccine-based approaches to squamous cell carcinoma of the head and neck.
Oral Dis. 2007 Jan;13(1):17-22. doi: 10.1111/j.1601-0825.2006.01329.x.
3
[Immunomodulation as innovative therapy for head and neck tumors : Current developments].
HNO. 2016 Jul;64(7):470-8. doi: 10.1007/s00106-016-0131-0.
4
Immunotherapy in head and neck cancer: current practice and future possibilities.
J Laryngol Otol. 2009 Jan;123(1):19-28. doi: 10.1017/S0022215108003356. Epub 2008 Sep 2.
5
[Immunotherapy: a new alternative treatment for head and neck squamous cell carcinoma].
Bull Cancer. 2007 Sep;94(9):793-7.
6
Genetically engineered tumor cell vaccine in a head and neck cancer model.
Laryngoscope. 2003 Mar;113(3):552-6. doi: 10.1097/00005537-200303000-00029.
7
Evaluation of Cetuximab in combination with radiotherapy or chemotherapy against advanced squamous cell carcinoma of the head and neck.
Shanghai Kou Qiang Yi Xue. 2008 Feb;17(1):1-5.
8
Targeted therapies in squamous cell carcinoma of the head and neck.
Cancer. 2009 Mar 1;115(5):922-35. doi: 10.1002/cncr.24123.
9
Targeted therapies for squamous cell carcinoma of the head and neck: current knowledge and future directions.
Cancer Treat Rev. 2014 Apr;40(3):390-404. doi: 10.1016/j.ctrv.2013.09.007. Epub 2013 Sep 14.
10
Impact of genetic targets on therapy in head and neck squamous cell carcinoma.
Adv Exp Med Biol. 2013;779:165-77. doi: 10.1007/978-1-4614-6176-0_7.
引用本文的文献
1
Activities of stromal and immune cells in HPV-related cancers.
J Exp Clin Cancer Res. 2018 Jul 5;37(1):137. doi: 10.1186/s13046-018-0802-7.
2
hrHPV E5 oncoprotein: immune evasion and related immunotherapies.
J Exp Clin Cancer Res. 2017 May 25;36(1):71. doi: 10.1186/s13046-017-0541-1.
3
Immunotherapy of HPV-associated cancer: DNA/plant-derived vaccines and new orthotopic mouse models.
Cancer Immunol Immunother. 2015 Oct;64(10):1329-38. doi: 10.1007/s00262-015-1734-0. Epub 2015 Jul 3.
4
Immunologic treatments for precancerous lesions and uterine cervical cancer.
J Exp Clin Cancer Res. 2014 Mar 26;33(1):29. doi: 10.1186/1756-9966-33-29.
5
Immunotherapy in new pre-clinical models of HPV-associated oral cancers.
Hum Vaccin Immunother. 2013 Mar;9(3):534-43. doi: 10.4161/hv.23232. Epub 2013 Jan 7.
6
Exogenous incorporation of neugc-rich mucin augments n-glycolyl sialic acid content and promotes malignant phenotype in mouse tumor cell lines.
J Exp Clin Cancer Res. 2009 Dec 1;28(1):146. doi: 10.1186/1756-9966-28-146.
本文引用的文献
1
An E7-based therapeutic vaccine protects mice against HPV16 associated cancer.
Vaccine. 2009 May 26;27(25-26):3395-7. doi: 10.1016/j.vaccine.2009.01.068. Epub 2009 Feb 5.
2
Overcoming obstacles to the effective immunotherapy of human cancer.
Proc Natl Acad Sci U S A. 2008 Sep 2;105(35):12643-4. doi: 10.1073/pnas.0806877105. Epub 2008 Aug 27.
3
Rapid tolerization of virus-activated tumor-specific CD8+ T cells in prostate tumors of TRAMP mice.
Proc Natl Acad Sci U S A. 2008 Sep 2;105(35):13003-8. doi: 10.1073/pnas.0805599105. Epub 2008 Aug 22.
4
Antitumor activity of DNA vaccines based on the human papillomavirus-16 E7 protein genetically fused to a plant virus coat protein.
Hum Gene Ther. 2008 Apr;19(4):354-64. doi: 10.1089/hum.2007.122.
5
Immunotherapy for head and neck cancer.
J Biomed Sci. 2008 May;15(3):275-89. doi: 10.1007/s11373-008-9247-x. Epub 2008 Apr 5.
6
Head and neck cancer immunotherapy: clinical evaluation.
Curr Oncol Rep. 2008 Mar;10(2):162-9. doi: 10.1007/s11912-008-0025-8.
7
Anti-tumor vaccines in head and neck cancer: targeting immune responses to the tumor.
Curr Cancer Drug Targets. 2007 Nov;7(7):633-42. doi: 10.2174/156800907782418310.
8
FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab.
J Clin Oncol. 2007 Aug 20;25(24):3712-8. doi: 10.1200/JCO.2006.08.8021.
9
A unique subset of CD4+CD25highFoxp3+ T cells secreting interleukin-10 and transforming growth factor-beta1 mediates suppression in the tumor microenvironment.
Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4345-54. doi: 10.1158/1078-0432.CCR-07-0472.
10
Human papillomavirus therapeutic vaccines in head and neck tumors.
Expert Rev Anticancer Ther. 2007 May;7(5):753-66. doi: 10.1586/14737140.7.5.753.
Zotero 插件